Asia FX muted, dollar nurses losses as Trump tariffs take effect
LONDON - Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF), a biotechnology firm focused on longevity gene therapies, has reached a pivotal stage in the patent process for its SIRT6 gene variants in Japan. The Japanese Patent Office has moved the company’s application, which is key to its therapeutic platform targeting age-related diseases, to the national examination phase.
The patent application, entitled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," was initially submitted on May 13, 2022. It is co-owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine, with Genflow holding the exclusive license.
SIRT6 is implicated in genomic stability, metabolic regulation, and healthy aging, making it a critical component of Genflow’s product pipeline. The progression of the patent application in Japan, a country known for its rapidly aging population, is a strategic move in Genflow’s efforts to secure broad international patent protection.
Dr. Eric Leire, CEO of Genflow Biosciences, expressed the company’s satisfaction with the advancement of their intellectual property protection, emphasizing the strategic importance of Japan in their global positioning as a leader in longevity gene therapy.
Genflow continues to develop its preclinical and clinical programs, focusing on age-related pathologies using the SIRT6 gene variants. The company’s lead compound, GF-1002, which delivers a centenarian variant of the SIRT6 gene, has shown promising preclinical results. Clinical trials for GF-1002, expected to commence in 2025, will investigate its potential in treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), a common chronic liver disease currently lacking effective treatments.
This advancement is based on a press release statement and represents a significant step for Genflow Biosciences in the field of gene therapy for aging.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.